What are the IDSA guidelines for the diagnosis and treatment of skin and soft‑tissue infections?

IDSA Guidelines for Diagnosis and Treatment of Skin and Soft Tissue Infections

The 2014 IDSA guidelines provide a comprehensive, severity-based approach to managing SSTIs, with clinical judgment as the cornerstone of diagnosis and early surgical intervention plus broad-spectrum antibiotics as the foundation for life-threatening infections 1.

Diagnosis

Clinical Assessment Priority

Clinical judgment trumps imaging studies for diagnosis 1. High clinical suspicion remains paramount - imaging may delay definitive treatment and has poorly defined sensitivity/specificity 1.

Key Diagnostic Features to Identify

For Necrotizing Fasciitis (the most critical to recognize):

• Pain disproportionate to physical findings
• Skin necrosis or bullae formation
• Gas in soft tissues on imaging or palpation
• Profound systemic toxicity (fever, hypotension)
• Rapid progression despite antibiotics
• Easy dissection along fascial planes with blunt instrument 1

Surgical exploration findings (definitive diagnosis):

• Swollen, dull gray fascia with stringy necrosis
• Thin brownish exudate (not true pus)
• Extensive undermining of tissues
• Easy blunt dissection of tissue planes 1

Imaging Recommendations

• MRI is the preferred modality for pyomyositis diagnosis 1
• CT or ultrasound are useful alternatives 1
• For necrotizing fasciitis: CT/MRI may show fascial plane edema but should not delay surgery 1

Microbiological Workup

• Obtain blood cultures and abscess/wound cultures before starting antibiotics 1
• Blood cultures are NOT recommended for mild cellulitis (commonly done incorrectly in practice) 2
• Abscess drainage should be sent for culture 1

Treatment Approach

Surgical Management

Immediate surgical consultation is mandatory for:

• Suspected or confirmed necrotizing fasciitis
• Gas gangrene
• Signs of systemic toxicity with aggressive infection 1

Surgical principles:

• Surgery is the PRIMARY therapeutic modality for necrotizing infections 1
• Return to OR every 24-36 hours after initial debridement until no further debridement needed 1
• Aggressive fluid resuscitation is essential (wounds discharge copious tissue fluid) 1

For simple abscesses:

• Incision and drainage alone is sufficient if minimal systemic signs (temp <38.5°C, WBC <12,000, pulse <100) 1
• Antibiotics are unnecessary with adequate drainage in these cases 1
• Prophylactic antibiotics not recommended as bacteremia is rare 1

Antibiotics indicated after I&D when:

• Temperature >38.5°C OR heart rate >110 bpm
• Erythema extending >5 cm beyond wound margins
• Give short course (24-48 hours) 1

Antimicrobial Therapy

For Necrotizing Fasciitis (Polymicrobial)

Empiric broad-spectrum coverage must include MRSA plus anaerobes 1:

Single-drug options:

• Piperacillin-tazobactam 3.375g q6h or 4.5g q8h IV
• Imipenem-cilastatin 500mg q6h IV
• Meropenem 1g q8h IV
• Ertapenem 1g q24h IV 1

PLUS one of these for MRSA coverage:

• Vancomycin 15mg/kg q12h IV
• Linezolid
• Daptomycin 1

Combination regimen alternatives:

• Ceftriaxone 1g q24h + metronidazole 500mg q8h IV
• Fluoroquinolone (ciprofloxacin 400mg q12h IV or levofloxacin 750mg q24h IV) + metronidazole 500mg q8h IV 1

Duration: Continue until no further debridement needed, clinical improvement, and afebrile for 48-72 hours 1

For Group A Streptococcal Necrotizing Fasciitis

Penicillin PLUS clindamycin is mandatory 1:

• Clindamycin suppresses toxin and cytokine production
• Superior to penicillin alone in animal models and observational studies
• Add penicillin due to potential clindamycin resistance (though <5% in US invasive strains) 1
• Macrolide resistance varies geographically (US <5%, Germany 8.2%, Spain 18.3%) 1

Narrow therapy once pathogen identified 1

For Pyomyositis

Empiric therapy:

• Vancomycin for MRSA coverage 1
• Add gram-negative coverage (e.g., ceftriaxone, fluoroquinolone) if immunocompromised or open trauma 1

Definitive therapy for MSSA:

• Cefazolin OR nafcillin/oxacillin 1

For Surgical Site Infections

Location-based approach 1:

Clean surgery (trunk/extremity away from axilla/perineum):

• Oxacillin/nafcillin 2g q6h IV
• Cefazolin 0.5-1g q8h IV
• Cephalexin 500mg q6h PO
• TMP-SMX 160-800mg q6h PO
• Vancomycin 15mg/kg q12h IV (if MRSA concern) 1

Surgery involving axilla/perineum:

• Metronidazole 500mg q8h IV PLUS
• Ciprofloxacin 400mg q12h IV or 750mg q12h PO, OR
• Levofloxacin 750mg q24h IV/PO, OR
• Ceftriaxone 1g q24h 1

Surgery involving GI/GU tract:

• Use regimens appropriate for intra-abdominal infections (polymicrobial coverage) 1

Common Pitfalls

Critical errors identified in practice studies 3, 2:

• Under-treatment based on IDSA guidelines increases treatment failure risk 2.65-fold 3
• Patients ≥70 years have 56% increased treatment failure risk regardless of adherence 3
• 71% of nonpurulent infections and 68.4% of purulent infections receive non-recommended antibiotics in EDs 2
• Excessive antibiotic use after simple abscess I&D (should not routinely occur) 2
• Blood cultures inappropriately done in 29% of mild cellulitis cases 2
• Overall guideline compliance in ED settings is only 20.1% 2

Key points to avoid errors:

• Do not delay surgery for imaging in suspected necrotizing infections
• Do not use antibiotics alone for abscesses requiring drainage
• Do not use TMP-SMX for nonpurulent cellulitis (lacks streptococcal coverage, though commonly misused) 2
• Do not continue antibiotics indefinitely - stop when clinically improved and afebrile 48-72 hours 1

Severity Classification Impact

Moderate infections have 3-fold increased treatment failure risk (aRR 2.98) and severe infections have 2-fold increased risk (aRR 2.27) compared to mild infections 3. This underscores the importance of accurate severity assessment and appropriate escalation of therapy.